Uncategorized

GRAIL remains focused on our mission to detect cancer early, when it can be cured. Revenue for the first quarter of 2023, comprised of Galleri test sales and biopharmaceutical partnerships revenue, was $26.7 million.  We continue to see uptake for Galleri in health systems, clinics and the employer and life insurance channels across the U.S. […]

Cancer accounts for just over a quarter of all deaths in England in a typical year. The NHS Long Term Plan (LTP) was published in January 2019 and set out stretching ambitions and commitments to improve cancer outcomes and services in England in the following ten years. Earlier and faster cancer diagnosis are among its

GRAIL continues to execute on our strategy towards population scale early cancer detection, and we are pleased with our progress in building the market for Galleri, driving our robust evidence generation programs and advancing future product development. Revenue for the fourth quarter of 2023 was $30 million and for the full year 2023 was $93

2023 was an exciting year for GRAIL. We are seeing continued strong early adoption of GalleriⓇ, our multi-cancer early detection (MCED) blood test, surpassing 150,000 commercial tests completed. Real-world use of Galleri has detected some of the most aggressive cancers in early stages, including endometrial, esophageal, gastrointestinal stromal, head & neck, liver, pancreatic and rectal

ELECTRONIC SUBMISSION AT www.regulations.gov Attn: Jarrod Collier, M.S.Designated Federal OfficerFDA Advisory CommitteeMolecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeDocket FDA–2023–N–4720US Food and Drug AdministrationSilver Spring, MD 20993 Dear Mr. Collier: GRAIL, LLC (“GRAIL” or “we”) appreciates the opportunity to submit a public comment to docket FDA–2023–N–4720 on the Molecular and Clinical Genetics

On December 17, 2023, Illumina announced it will divest GRAIL through a third-party sale or capital markets transaction, consistent with the European Commission\’s divestiture order, with the goal of finalizing the terms by the end of the second quarter of 2024.  “Throughout the regulatory process and as an independent and separate company, GRAIL delivered significant

A new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal from the American Association for Cancer Research (AACR), found that a large portion of cancers of all types can be cured when diagnosed at early stages, but are less likely to be curable once the cancer has metastasized.  Using a mixture cure model

GRAIL has received formal ISO 13485 certification from BSI, our EU Notified Body, for its Quality Management System. This certification applies to both of GRAIL’s sites, located in Menlo Park, CA and Durham, NC. Receiving ISO 13485 certification indicates that GRAIL has implemented robust policies and procedures for the development and manufacture of regulated medical

GRAIL is pleased to report continued progress on our mission to detect cancer early when it can be cured. Galleri adoption continues to grow, with more than 125,000 commercial tests returned as of September 30, 2023. We continue to grow our commercial reach with a number of new partnerships, including a multi-state collaboration with HCA

GRAIL has been named on Fortune’s 2023 Change the World List.  Now in its 9th year, Fortune’s Change the World list features companies addressing society’s biggest challenges – those who have had a positive social impact through activities that are part of their core business. Companies are assessed on factors including measurable social impact, business